# NATIONAL INSTITUTES OF HEALTH

## VIRTUAL DURC STAKEHOLDER ENGAGEMENT MEETING

**USG Policies for the Oversight of Life Sciences Dual Use Research of Concern**
**June 29, 2022; 12:00 PM – 4:30 PM (ET)**
**WEBLINK: https://videocast.nih.gov/watch=45698**

| AGENDA | |
|---|---|
| **12:00 – 12:10 PM** | **Welcome & Brief Policy Introduction**<br>*Lyric Jorgenson, PhD, Acting Associate Director for Science Policy, NIH* |
| **Session 1: USG DURC Policies – Scope & Definition** | |
| **12:10 – 1:20 PM** | **Key Questions**<br>• What are strengths and weaknesses of the scope of DURC policy oversight (i.e., 15 agents, 7 experimental types construct) in addressing potential risks across the life sciences research spectrum?<br>• Are there alternative approaches for overseeing research with dual use potential that effectively preserves benefits while mitigating risks?<br>• Given the evolving science and technology landscape, should the current DURC definition be revisited to address convergence with other scientific disciplines/sectors?<br><br>**Moderator**<br>*Gerald Parker, Jr., DVM, PhD, Associate Dean for Global One Health College of Veterinary Medicine and Biomedical Sciences, Texas A&M University*<br><br>**Invited Participants**<br>• *Jim LeDuc, PhD, Adjunct Professor, Department of Microbiology & Immunology, University of Texas Medical Branch at Galveston*<br>• *Jill Taylor, PhD, Senior Advisor for Scientific Affairs, Association of Public Health Laboratories*<br>• *Maria Chavez, Executive Director, Biocurious*<br>• *Drew Endy, PhD, Associate Professor of Engineering, Stanford University* |
| **1:20 – 1:30 PM** | **Break** |

| Session 2: USG DURC Policies – Implementation & Effects | |
|---|---|
| **1:30– 2:25 PM** | **Key Questions**<br>• How have these policies and their implementation impacted research institutions, researchers, and the broader research community? What works well and what could be improved?<br>• Are there different models for implementation that are more effective in achieve the goals of these policies? How, if at all, do institutions go beyond current DURC policy requirements to address other biosafety and biosecurity risks?<br>• What impacts have the policies had on publication, public communication, and dissemination of research findings and methodologies, and have they been effective at balancing transparency and risk?<br><br>**Moderator**<br>*Rachel Levinson, MA, Executive Director, National Research Initiatives, Knowledge Enterprise, Arizona State University*<br><br>**Invited Participants**<br>• *Kalpana Rengarajan, PhD, RBP, Director, Environmental Health and Safety Office, Emory University*<br>• *Joseph Kanabrocki, PhD, CBSP, Associate Vice President for Research Safety, University of Chicago*<br>• *Simon Anthony, PhD, Associate Professor, Pathology Microbiology and Immunology, UC Davis* |
| **2:25 – 2:55 PM** | **Public Comments** |
| **2:55 – 3:05 PM** | **Break** |

# NATIONAL INSTITUTES OF HEALTH

## VIRTUAL DURC STAKEHOLDER ENGAGEMENT MEETING

**WEBLINK:** https://videocast.nih.gov/watch=45698

| Session 3: USG DURC Policies – Anticipating the Future | |
|---|---|
| **3:05 – 4:15 PM** | **Key Questions**<br>• Looking forward, are there other aspects of balancing benefit and risk that should be integrated into the oversight and responsible conduct of DURC?<br>• What can we learn from other policy approaches, within the US and internationally, that are directly working to or could be used to identify, assess, and manage biosecurity and biosafety risks regarding the oversight of DURC?<br>• What opportunities/strategies exist to coalesce or integrate existing biosecurity governance, guidance, or policy?<br><br>**Moderator**<br>*Lyric Jorgenson, PhD, Acting Associate Director for Science Policy, NIH*<br><br>**Invited Participants**<br>• *David Gillum, MS, RBP, Assistant Vice President of Environmental Health and Safety, Arizona State University*<br>• *Christopher Viggiani, PhD, Associate Vice President, Research Integrity, Oregon State University*<br>• *Jennifer Kuzma, PhD, Distinguished Professor & Co-Director, Genetic Engineering & Society Center, School of Public and International Affairs, NC State University* |
| **4:15 – 4:30 PM** | **Closing Remarks**<br>*Lyric Jorgenson, PhD, Acting Associate Director for Science Policy, NIH* |
| **ADJOURN** | |